Blueprint Medicines Corporation (BPMC)

Market Cap	5.90B
Revenue (ttm)	508.82M
Net Income (ttm)	-67.09M
Shares Out	63.91M
EPS (ttm)	-1.07
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	777,180
Open	95.60
Previous Close	94.35
Day's Range	91.71 - 95.60
52-Week Range	80.68 - 121.90
Beta	0.62
Analysts	Buy
Price Target	123.61 (+34.0%)
Earnings Date	Feb 13, 2025

About BPMC

Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibitor for the treatment of indolent SM, and other mast cell disorders. It is also developing GAVRETO for the treatment of RET fusion-positive non-small cell lung cancer, altered thyroid carcinoma, and medul...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Apr 30, 2015
• Employees: 649
• Stock Exchange: NASDAQ
• Ticker Symbol: BPMC
• Website: https://www.blueprintmedicines.com

Financial Performance

In 2024, Blueprint Medicines's revenue was $508.82 million, an increase of 104.04% compared to the previous year's $249.38 million. Losses were -$67.09 million, -86.77% less than in 2023.

Analyst Forecast

According to 19 analysts, the average rating for BPMC stock is "Buy." The 12-month stock price forecast is $123.61, which is an increase of 34.00% from the latest price.

Price Target

$123.61

(34.00% upside)

Analyst Consensus: Buy